Interview part two: Chang Yi Wang, Chairperson & CEO, UBI Asia, and…
In the second part of this two-part interview, the Chairperson of UBI and UBI Asia offers her thoughts on the challenges and opportunities of the Chinese market, and explains her…
UBI is a privately held multinational biopharmaceutical company dedicated to the discovery, development and commercialization of immunotherapeutics and vaccines for chronic and infectious diseases.
The company’s product pipeline is filled with a new line of synthetic peptide-based biologicals for the treatment and prevention of Alzheimer’s Disease, AIDS, and Allergy, along with a portfolio of animal health diseases. These products are based on UBI’s proprietary designer peptides, vaccine formulation systems, and methods to manufacture therapeutic monoclonal antibodies. The company’s platform technologies are also being used to develop a line of biosimilar versions of widely used protein and antibody drugs whose patents are about to expire.
UBI’s proprietary designer peptide technology has been used to produce a line of blood screening diagnostics and the first successfully commercialized synthetic peptide vaccine. Additional revenue streams are generated from pharmaceutical contract manufacturing by the company’s subsidiary UBI-Asia and various sponsorships in product development.
Rm. E, 52F., No.7-5,
Sec. 5, Xinyi Rd.,
Xinyi Dist.,
Taipei City
11049,
Taiwan (R.O.C.)
Tel:886-2-8101-0101
Fax:886-2-8101-0100
In the second part of this two-part interview, the Chairperson of UBI and UBI Asia offers her thoughts on the challenges and opportunities of the Chinese market, and explains her…
In the first of this two-part interview, the chairperson of UBI and UBI Asia explains the work that her company has done to improve the landscape for Taiwanese pharma and…
The Second Generation National Health Insurance Act came into effect in January of this year, introducing a number of major changes to the Taiwanese healthcare framework. Can you please walk…
The chairman and CEO of Medigen shares his insights on a significant past three years for the company, which included both an IPO and major developments for the company’s innovative…
Giddi Pharma was founded in 1995. What was the vision behind the creation of the company? What founding principles did you have when you founded Giddi? When I founded this…
2010 is ScinoPharm’s thirteenth year of operations. Thirteen does not seem to be an unlucky number for you as your company is doing particularly well at the moment. Perhaps you…
You founded Orient Europharma in 1982, nearly 30 years ago. As you approach the 30 year mark, how has the company evolved to the way it is today, and how…
What is exciting about the Taiwanese market for Hospira today? Hospira is a US-based company, which used to be part of Abbott Laboratories. A major part of the portfolio for…
I was very surprised to see a company called ‘Standard Chemical and Pharmaceutical’ ranked amongst the top three local players in Taiwan: it seems as though your company is far…
Your grandfather started Chifu a long time ago: the business was registered in 1961. I imagine that the business today is completely different game from the one that it was…
Many key figures from the pharmaceutical industry have told us that the hospitals in Taiwan are the keystone to the country’s healthcare industry: the hospitals provide a very important service…
As a Taiwanese national and Country Head of Novartis Taiwan, what is your opinion on the current state of the pharmaceutical industry in Taiwan, and what are your hopes for…
Cheng-Ho Tsai, Mackay Memorial Hospital has a unique background and origins. How has this endured through the different stages of the pharmaceutical sector in Taiwan, and how do you see…
Academia Sinica celebrated its 80th anniversary in 2008. After this milestone, how does the institute define its activities today? Academia Sinica was founded more than eighty years ago, as the…
See our Cookie Privacy Policy Here
